Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2024 08:15 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023,...
January 05, 2024 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
December 21, 2023 07:31 ET | Source: Barinthus Biotherapeutics

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to University of Oxford to develop VTP-500
November 09, 2023 16:24 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level...
November 09, 2023 16:01 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023...
November 06, 2023 09:05 ET | Source: Barinthus Biotherapeutics

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly...
September 13, 2023 08:00 ET | Source: Vaccitech plc

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell...
August 10, 2023 08:00 ET | Source: Vaccitech plc

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell...
June 21, 2023 09:03 ET | Source: Vaccitech plc

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level,...
June 12, 2023 07:30 ET | Source: Vaccitech plc

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...